Abilita Bio, a San Diego, CA-based leader in discovering and developing membrane protein-targeted therapeutics, raised $7.5M in equity financing.
Two Bear Capital made the investment. Mike Goguen, Managing Partner at Two Bear Capital, has joined Abilita Bio’s board.
The company intends to use the funds to accelerate existing preclinical therapeutic programs, initiate efforts on additional targets, grow the team, and expand operations in San Diego.
Led by Mauro Mileni, PhD, CEO & Founder, Abilita Bio is an innovation-driven biotechnology company focused on discovering and developing therapeutic antibodies targeting the most challenging and medically important multi-span membrane proteins. Its validated drug discovery engine builds on the foundation of its EMP™ target evolution platform and deep membrane protein expertise to a suite of internal antibody discovery technologies.
Currently, the company has four active therapeutic antibody programs and is looking to move its first asset toward the clinical development candidate stage, as well as building partnerships with industry leaders that span from biologics to small molecules.
In addition, Dr. Michael Hanson recently joined the Abilita Bio team as CSO. He brings a track record of drug discovery and development in the GPCR space and most recently propelled multiple compounds into the clinic during his tenure at ShouTi (now Structure Therapeutics), where he was co-founder and CTO. Dr. Hanson also brings deep expertise in GPCR small molecule drug discovery, structural biology, structure-based drug design, and computational methods.
FinSMEs
21/02/2023